News

While present in most cases of SM, KIT D816V is not the only diagnostic marker of the disease.

A recent case report provides insight on the management of mast cell leukemia (MCL), a rare systemic mastocytosis (SM) subtype.

A recent case study describes how mast cell leukemia can present unusual symptoms that complicate diagnosis.

Systemic mastocytosis (SM) can lead to severe osteoporosis, bone pain and fractures, requiring specialized treatment.

Osteoporosis can be the presenting manifestation of systemic mastocytosis (SM), according to a recent case report.

A child was eventually diagnosed with systemic mastocytosis (SM) though he presented with none of the usual systemic symptoms.

Patients with bone marrow mast cell infiltration who do not meet WHO criteria for SM can still have symptoms and are at risk for osteoporosis.

Many cases of cutaneous mastocytosis remain confined to the skin, but some may indicate a risk for systemic mastocytosis (SM).

Avapritinib treatment improves survival outcomes and symptom management in patients with SM, its maker reported.

Physicians continue to raise standards in SM diagnosis and care, allowing patients with advanced SM to achieve better long-term outcomes.